What 6 Analyst Ratings Have To Say About ResMed
Portfolio Pulse from Benzinga Insights
Over the past three months, six analysts have shared their evaluations of ResMed (NYSE:RMD), revealing a mix of bullish, somewhat bullish, and indifferent outlooks. The average 12-month price target is $219.0, reflecting a 2.73% increase from the previous average. Analysts have adjusted their ratings and price targets based on recent developments, with some raising and others lowering their targets.
July 23, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on ResMed (NYSE:RMD) with an average 12-month price target of $219.0, reflecting a 2.73% increase from the previous average. Recent ratings show a mix of bullish, somewhat bullish, and indifferent outlooks.
The mixed analyst ratings and the slight increase in the average price target suggest a cautiously optimistic outlook for ResMed. The company's strong financial metrics, such as net margin and ROE, support this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100